Cardio Diagnostics Holdings (CDIO) EBITDA Margin (2022 - 2026)
Cardio Diagnostics Holdings (CDIO) posted EBITDA Margin of 66598.4% for Q1 2026, down 61.81% sequentially from 41159.55% in Q4 2025, and up 10686543.0% YoY from N/an in Q1 2025.
Cardio Diagnostics Holdings (CDIO) EBITDA Margin (2022 - 2026) Analysis & Trends
Cardio Diagnostics Holdings has reported EBITDA Margin for 5 years, with the latest figure at 66598.4% in Q1 2026.
- Quarterly EBITDA Margin rose 10686543.0% year-over-year to 66598.4% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 40074.58% (down 1073890.0% YoY) and the FY2025 annual result came in at 43737.46%, down 1975959.0% from the prior year.
- EBITDA Margin slipped to 66598.4% in Q1 2026 per CDIO's latest filing, from 41159.55% in the prior quarter.
- Over five years, EBITDA Margin peaked at 14398.71% in Q3 2023 and troughed at 250321.79% in Q4 2022.
- A 5-year average of 69447.71% and a median of 33608.2% in 2024 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2023 and 2025: EBITDA Margin surged 22128228 bps in 2023, then slumped 14735856 bps in 2025.
- Over 5 years, EBITDA Margin stood at 250321.79% in 2022, then surged by 88 bps to 29039.51% in 2023, then slipped by 16 bps to 33608.2% in 2024, then declined by 22 bps to 41159.55% in 2025, then plunged by 62 bps to 66598.4% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 66598.4%, 41159.55%, and 59950.86% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 17.93% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.36% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.75% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -35.57% |
| 10 | Cardio Diagnostics Holdings | 6.42 Mn | 835,350.96 | - | -27,950.50% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -27,950.50% |
| Mar 31, 2026 | -66,598.40% |
| Dec 31, 2025 | -41,159.55% |
| Sep 30, 2025 | -59,950.86% |
| Jun 30, 2025 | -22,457.51% |
| Mar 31, 2025 | -173,463.83% |
| Dec 31, 2024 | -33,608.20% |
| Sep 30, 2024 | -21,412.87% |
| Jun 30, 2024 | -16,295.55% |
| Mar 31, 2024 | -26,105.27% |
| Dec 31, 2023 | -29,039.51% |
| Sep 30, 2023 | -14,398.71% |
| Jun 30, 2023 | -148,008.17% |
| Dec 31, 2022 | -250,321.79% |